Safety and effectiveness of dupilumab in the real‐world treatment of atopic dermatitis in Japan: 1‐year interim analysis from a post‐marketing surveillance

• Asıl Yazarlar: Hidehisa Saeki (Yazar), Hiroyuki Fujita (Yazar), Katsuhisa Suzuki (Yazar), Kazuhiko Arima (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2023-06-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Objectives Atopic dermatitis (AD) is a common chronic inflammatory skin disorder in Japan. Dupilumab, a fully human monoclonal antibody, targets a shared subunit of the interleukin (IL)‐4 and IL‐13 receptors. Post‐marketing surveillance of the safety and effectiveness of dupilumab in adult...